Skip to main content
. 2016 Dec 9;15:1536012116673793. doi: 10.1177/1536012116673793

Figure 3.

Figure 3.

Positron emission tomography (PET)/computed tomography (CT) images in representative patient with Alzheimer disease (AD; A) and healthy elderly participant (B) at 45 to 70 minutes postadministration of 63Zn-zinc citrate. Hepatic uptake is largely prominent, while lower uptake by pancreas, spleen, kidneys and intestines, bone marrow, and brain was observed. No qualitative differences were observed in the PET images of whole-body distribution of 63Zn-zinc citrate in patients with AD relative to healthy participants.